F S&P 500
5,332.00 +4.75 (+0.09%) F Dow Jones
40,141.00 +4.00 (+0.01%) F Nasdaq
18,659.75 +24.50 (+0.13%) E-mini Russell 2000 Index Futur
2,107.50 +2.00 (+0.09%) Petróleo
79.84 -0.22 (-0.27%) Oro
2,449.40 +32.00 (+1.32%)
Pasithea Therapeutics Corp. (KTTA)
Pasithea Therapeutics Corp.
1111 Lincoln Road
Suite 500
Miami Beach, FL 33139
United States
702 514 4174
https://www.pasithea.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 8
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder, MD & Executive Chairman | 250k | N/D | 1948 |
| Dr. Tiago Reis Marques M.D., Ph.D. | CEO & Director | 480k | N/D | 1978 |
| Mr. Daniel H. Schneiderman | Chief Financial Officer | 345.94k | N/D | 1978 |
| Dr. Graeme Currie Ph.D. | Chief Development Officer | 346.62k | N/D | 1967 |
| Dr. Yassine Bendiabdallah Ph.D. | COO & Head of UK Clinics | N/D | N/D | 1984 |
Descripción
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Gestión corporativa
La calificación ISS Governance QuickScore de Pasithea Therapeutics Corp. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
